Literature DB >> 24598781

Induced pluripotent stem cells reveal functional differences between drugs currently investigated in patients with hutchinson-gilford progeria syndrome.

Sophie Blondel1, Anne-Laure Jaskowiak, Anne-Laure Egesipe, Amelie Le Corf, Claire Navarro, Véronique Cordette, Cécile Martinat, Yacine Laabi, Karima Djabali, Annachiara de Sandre-Giovannoli, Nicolas Levy, Marc Peschanski, Xavier Nissan.   

Abstract

Hutchinson-Gilford progeria syndrome is a rare congenital disease characterized by premature aging in children. Identification of the mutation and related molecular mechanisms has rapidly led to independent clinical trials testing different marketed drugs with a preclinically documented impact on those mechanisms. However, the extensive functional effects of those drugs remain essentially unexplored. We have undertaken a systematic comparative study of the three main treatments currently administered or proposed to progeria-affected children, namely, a farnesyltransferase inhibitor, the combination of an aminobisphosphonate and a statin (zoledronate and pravastatin), and the macrolide antibiotic rapamycin. This work was based on the assumption that mesodermal stem cells, which are derived from Hutchinson-Gilford progeria syndrome-induced pluripotent stem cells expressing major defects associated with the disease, may be instrumental to revealing such effects. Whereas all three treatments significantly improved misshapen cell nuclei typically associated with progeria, differences were observed in terms of functional improvement in prelamin A farnesylation, progerin expression, defective cell proliferation, premature osteogenic differentiation, and ATP production. Finally, we have evaluated the effect of the different drug combinations on this cellular model. This study revealed no additional benefit compared with single-drug treatments, whereas a cytostatic effect equivalent to that of a farnesyltransferase inhibitor alone was systematically observed. Altogether, these results reveal the complexity of the modes of action of different drugs, even when they have been selected on the basis of a similar mechanistic hypothesis, and underscore the use of induced pluripotent stem cell derivatives as a critical and powerful tool for standardized, comparative pharmacological studies.

Entities:  

Keywords:  Aging; Drug development; Mesenchymal stem cells; Pluripotent stem cells; Progeria

Mesh:

Substances:

Year:  2014        PMID: 24598781      PMCID: PMC3973719          DOI: 10.5966/sctm.2013-0168

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  30 in total

1.  A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects.

Authors:  Jinqiu Zhang; Qizhou Lian; Guili Zhu; Fan Zhou; Lin Sui; Cindy Tan; Rafidah Abdul Mutalif; Raju Navasankari; Yuelin Zhang; Hung-Fat Tse; Colin L Stewart; Alan Colman
Journal:  Cell Stem Cell       Date:  2010-12-23       Impact factor: 24.633

Review 2.  [Human pluripotent stem cells: opening key for pathological modeling].

Authors:  Yves Maury; Morgane Gauthier; Marc Peschanski; Cécile Martinat
Journal:  Med Sci (Paris)       Date:  2011-04-28       Impact factor: 0.818

3.  Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.

Authors:  Kan Cao; John J Graziotto; Cecilia D Blair; Joseph R Mazzulli; Michael R Erdos; Dimitri Krainc; Francis S Collins
Journal:  Sci Transl Med       Date:  2011-06-29       Impact factor: 17.956

4.  Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.

Authors:  Leslie B Gordon; Monica E Kleinman; David T Miller; Donna S Neuberg; Anita Giobbie-Hurder; Marie Gerhard-Herman; Leslie B Smoot; Catherine M Gordon; Robert Cleveland; Brian D Snyder; Brian Fligor; W Robert Bishop; Paul Statkevich; Amy Regen; Andrew Sonis; Susan Riley; Christine Ploski; Annette Correia; Nicolle Quinn; Nicole J Ullrich; Ara Nazarian; Marilyn G Liang; Susanna Y Huh; Armin Schwartzman; Mark W Kieran
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-24       Impact factor: 11.205

5.  Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs.

Authors:  Guang-Hui Liu; Keiichiro Suzuki; Jing Qu; Ignacio Sancho-Martinez; Fei Yi; Mo Li; Sachin Kumar; Emmanuel Nivet; Jessica Kim; Rupa Devi Soligalla; Ilir Dubova; April Goebl; Nongluk Plongthongkum; Ho-Lim Fung; Kun Zhang; Jeanne F Loring; Louise C Laurent; Juan Carlos Izpisua Belmonte
Journal:  Cell Stem Cell       Date:  2011-05-19       Impact factor: 24.633

Review 6.  Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders.

Authors:  John J Graziotto; Kan Cao; Francis S Collins; Dimitri Krainc
Journal:  Autophagy       Date:  2012-01-01       Impact factor: 16.016

7.  Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy.

Authors:  Brinda Ravikumar; Rainer Duden; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2002-05-01       Impact factor: 6.150

8.  Effect of progerin on the accumulation of oxidized proteins in fibroblasts from Hutchinson Gilford progeria patients.

Authors:  Gabriela Viteri; Youn Wook Chung; Earl R Stadtman
Journal:  Mech Ageing Dev       Date:  2009-12-01       Impact factor: 5.432

9.  Unique preservation of neural cells in Hutchinson- Gilford progeria syndrome is due to the expression of the neural-specific miR-9 microRNA.

Authors:  Xavier Nissan; Sophie Blondel; Claire Navarro; Yves Maury; Cécile Denis; Mathilde Girard; Cécile Martinat; Annachiara De Sandre-Giovannoli; Nicolas Levy; Marc Peschanski
Journal:  Cell Rep       Date:  2012-06-21       Impact factor: 9.423

10.  Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome.

Authors:  Guang-Hui Liu; Basam Z Barkho; Sergio Ruiz; Dinh Diep; Jing Qu; Sheng-Lian Yang; Athanasia D Panopoulos; Keiichiro Suzuki; Leo Kurian; Christopher Walsh; James Thompson; Stephanie Boue; Ho Lim Fung; Ignacio Sancho-Martinez; Kun Zhang; John Yates; Juan Carlos Izpisua Belmonte
Journal:  Nature       Date:  2011-02-23       Impact factor: 49.962

View more
  26 in total

1.  Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.

Authors:  Leslie B Gordon; Monica E Kleinman; Joe Massaro; Ralph B D'Agostino; Heather Shappell; Marie Gerhard-Herman; Leslie B Smoot; Catherine M Gordon; Robert H Cleveland; Ara Nazarian; Brian D Snyder; Nicole J Ullrich; V Michelle Silvera; Marilyn G Liang; Nicolle Quinn; David T Miller; Susanna Y Huh; Anne A Dowton; Kelly Littlefield; Maya M Greer; Mark W Kieran
Journal:  Circulation       Date:  2016-07-12       Impact factor: 29.690

Review 2.  Current status of pluripotent stem cells: moving the first therapies to the clinic.

Authors:  Erin A Kimbrel; Robert Lanza
Journal:  Nat Rev Drug Discov       Date:  2015-09-22       Impact factor: 84.694

3.  Tissue-Specific Influence of Lamin A Mutations on Notch Signaling and Osteogenic Phenotype of Primary Human Mesenchymal Cells.

Authors:  Kseniya Perepelina; Polina Klauzen; Anna Kostareva; Anna Malashicheva
Journal:  Cells       Date:  2019-03-21       Impact factor: 6.600

Review 4.  Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells.

Authors:  Alison E Mungenast; Sandra Siegert; Li-Huei Tsai
Journal:  Mol Cell Neurosci       Date:  2015-12-04       Impact factor: 4.314

5.  Diminished Canonical β-Catenin Signaling During Osteoblast Differentiation Contributes to Osteopenia in Progeria.

Authors:  Ji Young Choi; Jim K Lai; Zheng-Mei Xiong; Margaret Ren; Megan C Moorer; Joseph P Stains; Kan Cao
Journal:  J Bone Miner Res       Date:  2018-08-01       Impact factor: 6.741

Review 6.  Pharmacotherapy to gene editing: potential therapeutic approaches for Hutchinson-Gilford progeria syndrome.

Authors:  Saurabh Saxena; Sanjeev Kumar
Journal:  Geroscience       Date:  2020-02-11       Impact factor: 7.713

Review 7.  Human induced pluripotent stem cells for monogenic disease modelling and therapy.

Authors:  Paola Spitalieri; Valentina Rosa Talarico; Michela Murdocca; Giuseppe Novelli; Federica Sangiuolo
Journal:  World J Stem Cells       Date:  2016-04-26       Impact factor: 5.326

Review 8.  Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA gene mutations.

Authors:  Susana Gonzalo; Ray Kreienkamp; Peter Askjaer
Journal:  Ageing Res Rev       Date:  2016-06-29       Impact factor: 10.895

9.  Functional comparison of induced pluripotent stem cell- and blood-derived GPIIbIIIa deficient platelets.

Authors:  Mathias Orban; Alexander Goedel; Jessica Haas; Kirstin Sandrock-Lang; Florian Gärtner; Christian Billy Jung; Barbara Zieger; Elvira Parrotta; Karin Kurnik; Daniel Sinnecker; Gerhard Wanner; Karl-Ludwig Laugwitz; Steffen Massberg; Alessandra Moretti
Journal:  PLoS One       Date:  2015-01-21       Impact factor: 3.240

10.  Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.

Authors:  Diana Gabriel; Daniela Roedl; Leslie B Gordon; Karima Djabali
Journal:  Aging Cell       Date:  2014-12-16       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.